Natco Pharma Ltd

NSE: NATCOPHARM · BSE: 524816 · Pharmaceuticals & Biotechnology · 36 announcements

Share price: ₹823.65
Market cap: ₹16,157 Cr
Revenue (annual): ₹4,078 Cr
Net profit (annual): ₹1,418 Cr
P/E (TTM): 14.1×Sector 47.4×
Promoter holding: 49.42%+0.00% QoQ
FII holding: 16.99%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

8 Jul 2026 12:56 IST NSE

Natco Pharma Board Meeting Outcome

Natco Pharma's board approved a ₹1,069 Crore cash acquisition of Adcock Ingram Holdings. The deal lifts Natco's stake to 49% in the South African firm.

Value: ₹1,069 Cr
Execution: Before end of July 2026

Read the filing ↗

8 Jul 2026 12:56 IST NSE

Board Meeting Outcome

Natco Pharma Board Meeting Outcome

Natco Pharma announced a board-approved acquisition of its South African subsidiary for ₹1,400 Crore cash. The deal aims to expand its geographic footprint.

Value: ₹1,400 Cr

Read the filing ↗

8 Jul 2026 12:04 IST BSE

Board Meeting Outcome

Natco Pharma Board Meeting Outcome

Board approved a Rs 1,400 Cr investment in Natco Pharma Africa and a Rs 1,069 Cr purchase to raise its Adcock Ingram stake to 49%. The deals boost Natco’s footprint.

Value: ₹2,469 Cr

Read the filing ↗